Regeneron (REGN) Tops Q4 EPS by $1.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
February 5, 2021 6:30 AM ESTTARRYTOWN, N.Y., Feb. 5, 2021 /PRNewswire/ --
Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019 Fourth quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 56% to $1.17 billion versus fourth quarter 2019 and full year 2020 Dupixent global net sales increased 75% versus 2019 Fourth quarter 2020 GAAP diluted EPS was $10.24 and non-GAAP diluted EPS(1) was $9.53 REGEN-COV... More